Pharmaceutical Outsourcing Q2 2024 - 24

INTERVIEW
AN INTERVIEW WITH...
Gianmarco Negrisoli
President
Flamma USA
How has consolidation in the
pharmaceutical outsourcing industry
impacted the services and offerings of
CDMOs like Flamma?
The continued consolidation of CDMOs into larger conglomerates is
definitely bringing new dynamics to the outsourcing market. The onestop-shop
is a growth model that is often adopted. Private Equity (PE)
backed CDMOs are often driven by the pressure for financial results and
constant growth. In the last decade, many drug substance (DS) CDMOs
have reached into the drug product (DP) space through mergers and
acquisitions. While some have been successful, this model has often
shown how consolidated companies operate in silos and ultimately
bring little added value to customers.
In fact, many CDMOs have sold their finished dosage DP operations
to concentrate on DS manufacturing. Flamma continues to pursue
a strategy of organic growth and believes to stay focused on what
we do best: organic chemistry for APIs. This means diversifying our
services within our core chemistry competences. For example, we
have been focusing on hydrogenation, flow processes, high potency,
and green chemistry.
While Flamma is considered to be leaders in the amino acid space, we
prefer to continue to invest in our know-how, increase our capacity and
adopt new processes and technology instead of gambling on acquiring
a company in a different market segment. We believe partnerships with
specialized companies on adjacent fields is a great option to leverage
what each partner brings to the table. By offering a centralized project
management approach, this makes it easy for the customer to follow
their drug through the different stages of development.
In summary, while many CDMOs experience significant growth due
to consolidation, Flamma has continued to evolve by diversifying
services, expanding capabilities, and forming strategic alliances.
In what ways does Flamma differentiate
itself from other CDMOs in the industry,
particularly considering its site in
Malvern, PA?
Flamma offers a unique model in the CDMO industry. By having three
sites in Italy along with a site in the USA and a site in China, we are
able to leverage the capabilities and strategically take advantage of
each location to offer speed, commercial supply reliability and back
integration where needed. In particular, our Malvern, PA site offers the
ability to work on early stage small molecule projects. In addition to
R&D and analytical development capabilities, we have 5 kilo labs with
reactors up to 100 L, a 300 L (10 bar) hydrogenation unit and a pilot
plant with volumes to 500 L that are all operating under cGMP.
Pharmaceutical Outsourcing | 24 | April/May/June 2024
Pharmaceutical Outsourcing Q2 2024

Table of Contents for the Digital Edition of Pharmaceutical Outsourcing Q2 2024
